Benchmark Electronics Lifts Outlook After Q1 Beat

Benchmark Electronics ((BHE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Benchmark Electronics struck an upbeat tone on its latest earnings call, as management detailed a clean beat on first‑quarter expectations and a meaningful raise to full‑year guidance. Executives acknowledged some cyclical and seasonal headwinds, but emphasized broad‑based demand, strong end‑market outperformance, and solid cash generation as reasons for growing confidence in the company’s multi‑year trajectory.

Revenue Beat and Solid EPS Performance

Benchmark reported Q1 revenue of $677 million, up 7% year over year and landing toward the high end of its guidance range. Non‑GAAP EPS came in at $0.58, also toward the upper end of the $0.53–$0.59 outlook, underscoring consistent execution despite seasonal softness in some segments.

Full-Year Outlook Raised to High Single Digits

Management lifted its full‑year revenue growth expectation to 9%–10%, a notable step up from prior mid‑single‑digit assumptions. The company also expects EPS to grow faster than revenue, pointing to operational execution and tight expense control as key levers for margin and earnings expansion.

Medical and AC&C Drive High-Growth Tailwinds

Medical revenue surged 24% year over year, reinforcing this segment as a structural growth engine for the business. AC&C revenue jumped 41%, powered by AI‑linked ramps in liquid cooling, high‑performance compute, and clustered AI solutions, and Benchmark highlighted a recent award as HPE’s 2026 Manufacturing Partner of the Year as further validation.

Semi-Cap Recovery and Capacity Expansion

The Semi‑Cap segment showed sequential improvement with management characterizing the backdrop as a recovery, citing double‑digit sequential growth and underlying demand momentum. For 2024, Benchmark expects mid‑teens growth in Semi‑Cap and is preparing additional capacity, with its Penang PT building 4 on track to begin operations in the third quarter.

Improving Margins and Profitability Year over Year

Non‑GAAP gross margin improved 20 basis points year over year to 10.3%, while non‑GAAP operating margin also rose 20 basis points to 4.8%. Management attributed the gains to operational leverage and disciplined execution, even as the quarter absorbed typical seasonal effects and higher variable compensation.

Robust Cash Generation and Strong Balance Sheet

Operating cash flow reached $47 million in the quarter, translating to $29 million in free cash flow. The company ended Q1 with a net cash position of about $120 million, $325 million of cash on hand, and $486 million of available borrowing capacity, giving it ample flexibility to fund growth and shareholder returns.

Capital Investment and Shareholder Returns

Benchmark invested roughly $18 million in capex during Q1 and now expects full‑year capital spending toward the high end of 2.0%–2.5% of revenue as it supports growth programs. Shareholders also benefited from $6 million in cash dividends and $6 million of share repurchases, with about $117 million still authorized for future buybacks.

Bookings Support Confidence in Growth Outlook

Management pointed to another quarter of solid bookings as a key driver of its confidence in the upgraded full‑year revenue guide. The order flow appears well balanced across multiple end markets, suggesting that the current growth trajectory is not reliant on any single customer or vertical.

Sequential Margin Pressure from Seasonality

Despite the year‑over‑year improvement, margins were lower than in Q4 as non‑GAAP gross margin dipped 30 basis points sequentially and operating margin fell 70 basis points. Executives tied this to typical seasonal volume patterns and higher variable compensation, framing the downtick as temporary rather than structural.

Softness in Industrial and Aerospace & Defense

Industrial revenue declined 3% year over year and Aerospace & Defense slipped 2%, reflecting some moderation after prior strength. Management also flagged that A&D may see further moderation into 2026 due to program timing, while still expecting a recovery in activity later as new awards ramp.

Ambiguity Around Semi-Cap Sequential Growth

While Semi‑Cap is clearly improving, the call included inconsistent comments on the exact scale of sequential growth, with the CEO citing double‑digit gains and other remarks suggesting a smaller step‑up. Even so, management reiterated its view that Semi‑Cap should deliver mid‑teens growth for the full year as utilization and new programs build.

Supply Chain and Cost Headwinds

The company noted emerging pockets of supply tightness, particularly in memory‑related components, which could create localized execution risk. Additionally, Q1 margins absorbed a slightly higher‑than‑guided non‑GAAP tax rate of 27.4% and incremental corporate and ramp‑related expenses, which management is monitoring closely.

Seasonality Weighs on Sequential Revenue and Earnings

Benchmark reminded investors that Q1 is seasonally softer for both revenue and margins, leading to some sequential declines from Q4. Management expects this near‑term dip to reverse through the rest of the year as volumes ramp, new programs scale, and cost initiatives support better profitability.

Guidance Signals Confidence in Accelerating Growth

For Q2, the company guided revenue to $700 million–$740 million, implying roughly 12% year‑over‑year growth at the midpoint, alongside modestly higher gross and operating margins and non‑GAAP EPS of $0.65–$0.71. Looking across 2024, Benchmark now targets 9%–10% revenue growth, faster‑growing operating income and earnings, continued Semi‑Cap strength, elevated but targeted capex, and healthy cash flow and liquidity metrics.

Benchmark’s earnings call painted a picture of a company steadily leaning into secular growth drivers in Medical, AI‑linked compute, and Semi‑Cap while navigating cyclical and seasonal bumps in other areas. For investors, the upgraded guidance, improving profitability, and solid balance sheet suggest a constructive setup, even as pockets of weakness and supply‑chain risk remain on the radar.